New kidney drug enters early human testing
NCT ID NCT06209177
First seen Jan 11, 2026 · Last updated May 15, 2026 · Updated 17 times
Summary
This early-stage study tests a new drug, ARO-CFB, in healthy people and patients with IgA nephropathy, a kidney disease. The main goal is to check safety and how the drug moves through the body. Participants receive either the drug or a placebo.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IGA NEPHROPATHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Auckland, 1010, New Zealand
Conditions
Explore the condition pages connected to this study.